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Abstract Reelin is an extracellular glycoprotein involved
in key cellular processes in developing and adult nervous
system, including regulation of neuronal migration, synap-
se formation, and plasticity. Most of these roles are medi-
ated by the intracellular phosphorylation of disabled-
1 (Dab1), an intracellular adaptor molecule, in turn medi-
ated by binding Reelin to its receptors. Altered expression
and glycosylation patterns of Reelin in cerebrospinal and
cortical extracts have been reported in Alzheimer’s disease.
However, putative changes in Reelin are not described in
natural prionopathies or experimental models of prion in-
fection or toxicity. With this is mind, in the present study,
we determined that Reelin protein and mRNA levels in-
creased in CJD human samples and in mouse models of
human prion disease in contrast to murine models of prion
infection. However, changes in Reelin expression appeared
only at late terminal stages of the disease, which prevent
their use as an efficient diagnostic biomarker. In addition,
increased Reelin in CJD and in in vitro models does not
correlate with Dab1 phosphorylation, indicating failure in
its intracellular signaling. Overall, these findings widen our
understanding of the putative changes of Reelin in
neurodegeneration.
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Introduction
Reelin is an extracellular matrix protein essential for proper
neuronal migration in laminated areas of the developing brain
[1, 2]. In adulthood, Reelin has been localized in synaptic
terminals (especially from GABAergic interneurons) and im-
plicated in neuronal plasticity [3, 4]. In fact, Reelin actively
participates as a key actor in several neural processes such us
cell survival [5] and synaptic plasticity [6–8] as well as in
pathological conditions such as ischemia [9, 10] and neurode-
generation [11–13]. These results point to the maintenance of
Reelin protein levels as crucial for correct homeostatic balance
in developing and adult nervous system. In neural tissue,
Reelin binds to Apolipoprotein E receptor 2 (ApoER2) and
Very Low-Density Lipoprotein Receptor (VLDLR), trigger-
ing tyrosine phosphorylation of disabled-1 (Dab1), a cytoplas-
mic adaptor protein, by kinases of the Src family [14–17].
Following phosphorylation, Dab1 protein recruits the p85α
subunit of phosphatidylinositol-3 kinase (PI3K), stimulating
AKT-phosphorylation, glycogen synthase kinase 3β
(GSK3β), and CrkL [18, 19].
Reelin protein levels in the brain could be modified by
several factors such as hormones [20–24], oxidative stress
[25], perinatal stress [26], and exercise [27]. Some of these
conditions (e.g., hormone misbalance and oxidative stress) are
common features in diseases such as schizophrenia [28, 29]
and autism [30], as well as neurodegenerative diseases such as
Alzheimer’s disease [31, 32] and prionopathies [33]. Indeed,
Reelin protein levels are altered in schizophrenia [34] and
autism [35] as well as in Alzheimer’s disease [36–38].
However, very few data have been reported concerning
Creutzfeldt-Jakob disease (CJD) or related models of infective
transmissible spongiform encephalopathies (TSEs).
Decreased Reelin levels has been reported in aging [39,
40], mild cognitive dementia, and Alzheimer’s disease [36,
41, 42]. Although a low number of Reelin-positive cells
have been reported in aged brains, the Reelin decrease in
Alzheimer’s disease is likely associated with their presence
in senile plaques enriched in aggregated β-amyloid [24, 43,
44]. In fact, it has been suggested that histologically [39]
and biochemically [12], Reelin binds to oligomeric β-
amyloid preventing its accumulation in senile plaques.
This is in contrast to other studies indicating increased
levels of Reelin in late stages (Braak stages III-VI) of
Alzheimer’s disease [38]. Nonetheless, current studies sug-
gest that reduced levels of Reelin in Alzheimer’s disease
increases the amyloid burden observed in the disease [7,
12, 45]. In addition, a recent study reports that Reelin pro-
duced in the presence of aggregated β-amyloid showed
altered glycosylation [46] and therefore was a non-
functional protein [11]. Thus, the combination of low pro-
tein levels and non-functional Reelin may constitute a vi-
cious circle that promotes the progression of the cognitive
impairment in Alzheimer’s disease by diminishing synaptic
function [13, 47] and cytoskeletal stability [11].
As indicated above, very few data on Reln mRNA or pro-
tein levels are reported in Creutzfeldt-Jakob disease or infec-
tive prionopathies. In fact, only a recent study analyzing
changes in mRNA expression by microarrays in RML-
infected cerebellar organotypic cultures indicated a slight de-
crease in Reln mRNA at late stages (38 and 45 days) post-
infection [48]. This decrease seemed likely to be associated
with the relevant granule cell death triggered by the RML
infection. In a previous study [49], we determined that mimet-
ic peptides in aggregated form of the human sequence of the
cellular prion protein (PrP106–126) were able to increase the
phosphorylation of Dab1. In parallel, our studies also pointed
to an increase in Dab1 phosphorylation and degradation in
CJD patients, especially in those with prion type I and Met/
Met 129 polymorphism [50]. Thus, high levels of p-Dab1
leading to low levels of Dab1 rely on low numbers of β-
amyloid plaques [50].
Taking this into account and as natural follow-up to our
previous studies, we aimed to explore in the present study
the putative changes of Reelin levels in prionopathies
employing cytotoxicity models using primary neuronal cul-
tures, prion-inoculated mice, and human sporadic CJD post-
mortem samples. Results demonstrate that neurons incubated
with mimetic prion peptides increased Reelin expression like-
ly by reactive oxygen species (ROS) production. In addition,
Reelin and RelnmRNA are increased in post-mortem samples
of CJD patients as well as in CJD-infected Tg340 mice in
contrast to mice infected with mouse prions.
Materials and Methods
Mouse Strains and Genotyping
Adult male C57Bl6/129sv-Prnp0/0 (B6129 PrnpZrchl/Zrchl
Zurich I) mice were purchased from the European Mouse
Mutant Archive (EMMA, Monterotondo, Italy) [51]. We
backcrossed to C57BL/6J for at least 8 generations to obtain
6–7 % of 129 microsatellites B6.129 Prnp0/0 and control lit-
termates B6.129 Prnp+/+. Specific primers to Prnp genotyp-
ing were designed in our laboratory based on the original
P3 and P10 primers as descr ibed [51] : neo: 5 ′ -
gccttctatcgccttcttgac-3′; 3′ NCnew: 5′-gctacaggtggataacccctc-
3′ and P10new: 5′-cataatcagtggaacaagccc-3′. 40 cycling con-
dition were 45″ 95 °C; 45″ 62 °C; 1′ 72 °C, followed by a final
extension at 72 °C for 5 min. Prnp-overexpressing mice
(Tga20) were purchased from EMMA (Monterotondo,
Italy). They were generated as described by Marek et al.
[52] and backcrossed in our lab with B6.129 Prnp0/0
mice for 7 generations. For Tga20 mice, the transgene
was detected using primers specific to the Tg20 allele
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5′-caaccgacgtgaagcattctgccta-3′ and 5′-cctgggactccttctg
gtaccgggtgacgc-3′ as indicated [53]. All experiments
were performed under the guidelines and protocols of
the Ethical Committee for Animal Experimentation
(CEEA) of the University of Barcelona, and the proto-
col for the use of animals in this study was reviewed
and approved by the CEEA of the University of
Barcelona (CEEA approval no. 276/16 and 141/15).
Mice Inoculated with Different Prion Strains
As model of mouse prion diseases, we used B6.129
Prnp+/+ or C57BL/6J intracranially inoculated with
two different mouse-adapted prion strains (22L, Mo-
BSE) or with GPI-anchorless PrPSC as previously de-
scribed [54, 55]. As mouse model of sCJD, we used
the Tg340 mouse line inoculated with sCJD prions
[56]. Tg340 mice were intracranially inoculated with
an sCJD isolate obtained from the UK CJD reference
center in Edinburgh [55]. Briefly, 6- to 10-week-old
female mice were anesthetized and inoculated with
2 mg of brain equivalent (20 μl of a 10 % brain ho-
mogenate) in the right parietal lobe using a 25-gauge
disposable hypodermic needle. The mice were observed
daily and their neurological status was assessed weekly.
When clinically progressive TSE disease was evident,
the animals were killed and their brains collected.
Brains from those animals were dissected and separated
brain zones were frozen at −80 °C. Mouse inoculation
experiments were carried out in strict accordance with
the recommendations in the guidelines of the Code for
Methods and Welfare Considerations in Behavioral
Research with Animals (Directive 86/609EC), and all
efforts were made to minimize suffering. Experiments
were approved by the Committee on the Ethics of
Animal Experiments of the author’s institutions (INIA
and INRA; and University of Santiago de Compostela,
15005AE/12/FUN01/PAT05/JRR3).
Human CJD Cases
The brains of 26 patients with sporadic CJD were ob-
tained from 3 to 8 h after death and immediately pre-
pared for morphological and biochemical studies. The
main clinical and pathological characteristics are sum-
marized in Table 1. For biochemical studies, samples
of the frontal cortex were frozen in liquid nitrogen
and stored at −80 °C until use. The standard neuropath-
ological study was carried out on de-waxed 4-μm thick
paraffin sections of several brain regions (see [50] for
description).
Primary Embryonic Neuronal Cultures
E15.5–16.5 mouse embryo brains were dissected and washed
in ice-cold 0.1 M PBS containing 6.5 mg/ml glucose. The
meninges were removed and the cortices isolated. Tissue
pieces were trypsinized for 15 min at 37 °C. After the addition
of horse serum and centrifugation, the cells were dissociated
by trituration in 0.1 M PBS containing 0.025 %DNAse with a
Table 1 Main clinical characteristics of sCJD and control cases in the
western blot study
Case number Gender Age Codon 129 PrP type
CJD1 M 25 MM 1
CJD2 M 79 MM 1
CJD3 F 82 MM 1
CJD4 F 63 VV 1
CJD5 F 54 MM 1
CJD6 F 65 MM 1
CJD7 M 52 MM 1
CJD8 M 61 MM 1
CJD9 F 60 MM 1
CJD10 M 56 MM 1
CJD11 M 74 MM 1
CJD12 F 87 MV 1
CJD13 F 85 MM 1
CJD14 F 70 MM 1
CJD15 F 64 MM 1
CJD16 M 55 VV 1
CJD17 M 73 MM 2
CJD18 F 67 MM 2
CJD19 F 63 MM 2
CJD20 F 76 VV 2
CJD21 F 52 VV 2
CJD22 M 76 VV 2
CJD23 M 71 VV 2
CJD24 M 66 VV 2
CJD25 F 70 MV 2
CJD26 M 77 MM 2
Control1 M 53
Control2 M 43
Control3 M 59
Control4 M 56
Control5 M 43
Control6 M 47
Control7 M 56
Control8 F 65
Control9 F 66
Control10 F 69
F female,Mmale,MMmethionine, V valine, PrPsc type 1 lower band of
glycosylated PrPsc of 21 kD, type 2 lower band of glycosylated PrPsc of
10 kD
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polished pipette. Dissociated cells were plated at ~3000 cells/
mm2 on plates (Nunc, Denmark) coated with poly-D-lysine
(Sigma, UK). The culture medium was Neurobasal supple-
mented with 2 mM glutamine, 6.5 mg/ml of glucose, antibi-
otics, and B27 (Invitrogen-Life Technologies, Belgium). After
72 h, AraC 5 μM (cytosine β-D-arabinofuranoside hydrochlo-
ride, C6645-100MG, Sigma) was added for 48 h to inhibit the
growth of dividing non-neuronal cells. Cultures contained up
to 95 % neurons (TUJ-1+) and were used after 15 days
in vitro.
PrP(106–126) Peptide Treatments
Prion protein fragments 106–126 (human) and scram-
bled prion peptide were from Sigma. Peptides (1 μg/
μl) were dissolved in PBS 0.1 M and allowed to spon-
taneously aggregate at room temperature for 5 h and
checked at electron microscopy. After aggregation,
PrP(106–126) or scrambled peptides were added to the
cortical cultures, which were incubated over a range of
times from 30 min to 4 days. Afterward, the culture
medium was collected at 4 °C and peptide-treated cells
were scraped in homogenization buffer containing
150 mM NaCl, 1 mM EDTA, 10 % glycerol, 1 %
Triton X-100, protease inhibitor cocktail (Roche
Farma), and phosphatase inhibitors (10 mM tetrasodium
pyrophosphate 200 μM sodium orthovanadate, and
10 mM sodium fluoride). NADPH oxidase-inhibitor
DPI (diphenyleneiodonium chloride) (10 μM) and N-
acetyl-L-cysteine (NAC) (20 mM) were from Sigma.
Determination of Cell Death
Cell death was assessed using a propidium iodide (PI,
Sigma-Aldrich) [57]. Briefly, shortly after treatments in
24-well plates, 30 μM PI was added to each well. PI
fluorescence was measured using a FL600 Microplate
Fluorescence Reader (BioTeck). Spectrofluorometer analy-
sis and settings were as follows: 530-nm excitation, 645-
nm emission, and data were recorded in relative fluores-
cence units. As an index of cell death that was not related
to actual differences between samples, baseline fluores-
cence F 1 was measured 1 h after addition of PI.
Subsequent fluorescence readings were taken at several
time points (F n) after the onset of the experiment, keep-
ing the cells in the incubator between measurements.
Finally, the cells were permeabilized for 10 min at
37 °C with 500-μM digitonin (Sigma Aldrich) to obtain
the maximum fluorescence (100 % of cell death or F max).
The percentage of cell death (%CD) was calculated as
follows: %CD = 100 × (Fn − F1)/(Fmax − F1) [57].
Western Immunoblot
Samples from different sources were processed for western
blot, including human post-mortem samples, mice cortical
extract, and cultured cells. The collected samples were ho-
mogenized in (10 % w/v) of 50 mM Tris–HCl, pH 7.4/
150 mM NaCl/0.5 % Triton X-100/0.5 % Nonidet P-40 and
a mixture of protease inhibitor cocktail (Roche) and phospha-
tase inhibitors (10 mM tetrasodium pyrophosphate, 200 μM
sodium orthovanadate, and 10 mM sodium fluoride). After
this, the samples were centrifuged at 15,000×g for 20 min at
4 °C. The resulting supernatant was normalized for protein
content using BCA kit (Pierce). Cell extracts were boiled at
96 °C for 3 min, followed by 6 % SDS electrophoresis, and
electro-transferred to nitrocellulose membranes for 2 h at 4 °C.
Membranes were then blocked with 5 % non-fat milk in 0.1M
Tris-buffered saline (pH 7.4) for 2 h and incubated overnight
in 0.5 % blocking solution containing primary antibodies.
After incubation with peroxidase-tagged secondary antibodies
(1:2000 diluted), the membranes were revealed by ECL-plus
chemiluminescence western blot kit (Amershan-Pharmacia
Biotech). In our experiments, each nitrocellulose membrane
was used to detect reelin (4G10, Millipore), ApoER2
(Milipore), VLDL (MIllipore), β-actin (1:10,000; Sigma), or
tubulin (1:5000; Sigma) PrPC levels. For Dab1 immunopre-
cipitation, 1000 μg of total protein was incubated with αDab1
(Exalpha Biologicals, Watertown, MA, USA) at 4 μg in
500-μl total volume overnight at 4 °C. Afterward, immune
complexes were precipitated using Protein-G-Sepharose
(Amersham-Pharmacia Biotech; Barcelona, Spain) at 4 °C
for 90 min. After centrifugation, proteins were eluted in
twice-concentrated Laemmli sample buffer at 96 °C for
5 min, followed by 10 % SDS-PAGE and immunoblotting
us ing the an t i -phospho ty ros ine 4G10 (Ups ta t e
Biotechnology Inc., NY, USA). The membranes were re-
probed with ab7522 antibody for total Dab1 detection
(Abcam, Cambridge, MA, USA) [49, 50].
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time PCR was performed on total RNA ex-
tracted with mirVana’s isolation kit (Ambion, Austin, TX,
USA) from the cortex of CJD patients or from Tg340 mice.
Purified RNAs were used to generate the corresponding
cDNAs, which served as PCR templates for mRNA quantifi-
cation. Two different sets of primers were used. First for the
Tg340 mice, quantitative RT-PCR assays were performed in
duplicate on cDNA samples obtained from the retro-
transcription reaction diluted 1:20 in 384-well optical plates
(Kisker Biotech, Steinfurt, GE) using the ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems). The reac-
tions were carried out using 20× TaqMan gene expression
assays for genes and 2× TaqMan Universal PCR Master Mix
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(Applied Biosystems). The reactions were conducted using
the following parameters: 50 °C for 2 min, 95 °C for
10 min, 40 cycles at 95 °C for 15 s and 60 °C for
1 min. The fold change was determined using the
Eq. 2−ΔΔCT. Similar results were obtained using two dif-
ferent housekeeping genes for normalization (HPRT and
GUSB). The assay numbers of RT-qPCR analysis were
Mm00465200_m1 and Mm00465231_m1 for Reelin,
Mm00446968_m1 for HPRT, and Mn00446958_g1 for
the GUSB housekeeping genes.
For the human CJD samples, PCR amplification and detec-
tion were performed with the ROCHE LightCycler 480 detector,
using 2× SYBR GREEN Master Mix (Roche) as reagent, fol-
lowing the manufacturer’s instructions. The reaction profile was
denaturation-activation cycle (95 °C for 10 min) followed by
40 cycles of denaturation-annealing-extension (95 °C for
10 min, 72 °C for 1 min, 98 °C continuous). mRNA levels were
calculated using the LightCycler 480 software. Data were ana-
lyzed with SDS 1.9.1 software (Applied Biosystems) following
the 2−ΔΔCT method of Applied Biosystems. Primers were as
follows: Reln (5 ′-actctgtcaacagctcaagc-3 ′) and (5 ′-
tggtcaattgcccagctttg-3′). The results were normalized for the ex-
pression levels of the housekeeping gene, gapdh (5′-
aggtcggtgtgaacggatttg-3′) and (5′-tgtagaccatgtagttgaggtca-3′),
which were quantified simultaneously with the target gene [58].
Immunohistochemistry and In Situ Hybridization
In situ hybridization was carried out as described previ-
ously [59] on 40-μm frozen adult brain sections. Both
sense and antisense riboprobes were labeled with
digoxigenin according to the manufacturer’s instructions
(Roche Farma). For the immunohistochemistry studies
of frozen brain sections, tissue was incubated with pri-
mary antibodies overnight, followed by appropriate sec-
ondary antibodies. Tissue binding primary antibody was
detected using the ABC method. Briefly, free-floating
sections were rinsed in 0.1 M PBS, and endogenous
peroxidase activity was blocked by incubation in 3 %
H2O2 and 10 % methanol dissolved in 0.1 M PBS.
After extensive rinsing, sections were incubated in
0.1 M PBS containing 0.2 % gelatin, 10 % normal goat
serum, 0.2 % glycine, and 0.2 % Triton-X 100 for 1 h
at room temperature. Afterward, sections were incubated
for 24 h at 4 °C with the primary antibody: α-calbindin
and α-parvalbumin (1:2000 diluted; Swant Antibodies,
Switzerland). After that, sections were incubated with
secondary biotinylated antibodies (2 h, 1:200 diluted)
and streptavidin-horseradish peroxidase complex (2 h,
1:400 diluted). Peroxidase activity was revealed with
0.025 % diaminobenzidine (DAB) and 0.003 % hydro-
gen peroxide. After rinsing, sections were mounted onto
slides, dehydrated, and cover-slipped with Eukitt™
(Merck). Samples were photo-documented using an
Olympus BX61 microscope equipped with a cooled dig-
ital DP72L camera. For cell counting, the radial distri-
bution of Reln-, calbindin-, or parvalbumin-positive cells
was analyzed. Positive cells in individual layers were
counted with a ×20 objective in 500-μm thick vertical
strips covering the entire radial extent of the neocortex.
Fig. 1 a, b Example of western
blot determination of reelin in
Prnp+/+, Prnp0/0, and Tga20. The
quantification of the obtained
results is plotted in b. Each dot
corresponds to one experiment.
c–e Low power
photomicrographs illustrating the
distribution of Reln mRNA in the
cerebral cortex of 3-month-old
Prnp0/0 (c) and Prnp+/+ (d). e
Radial distribution of Reln-
positive neurons in Prnp0/0 and
Prnp+/+ adult mice. Cortical
layers are indicated on the Yaxis.
Bars represent the mean ± S.E.M.
of the total number of cells
counted in eight consecutive
sections of four adult mice per
genotype. No statistical
differences in the numbers of
Reln-positive cells were seen
between genotypes
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Densitometry and Statistical Processing
For quantification, developed films were scanned at
2400 × 2400 dpi (i800 MICROTEK high-quality film
scanner), and the densitometric analysis was performed
using Quantity One Image software analysis (Biorad,
Windows) and the Gel-Pro analyzer (Media Cybernetics,
Windows). Statistical analysis of the obtained data was
performed using Bonferroni post hoc test (Multiple com-
parison test) using GraphPad Prism 5.0c (Mac OsX,
Grahpad). Data are presented as mean ± standard error
of the mean (S.E.M.). Differences between groups were
considered statistically significant at *P < 0.05.
Results
Adult Cortical Levels of Reelin Are Not Modified
by Changes in Prnp Dosage
Endogenous levels of Prnp are reduced around 50 % in CJD
patients [60]. This differs from what is reported in infected
mice [61]. Therefore, we aimed to determine putative changes
in the presence of Reelin in CJD patients and infection models
and to determine whether Prnp expression levels correlated
with changes in Reelin protein levels (Fig. 1). Cortical brain
extracts from Prnpo/o, Prnp+/+, and Tga20 mice were proc-
essed for reelin detection with western blotting (Fig. 1a, b).
Fig. 2 a Time course of Reelin,
ApoeR2, and VLDL expressions
in cortical cultures exposed to
80 μM aggregated PrP(106–126)
for 24 h and 4 days. Tubulin and
actin were used as control loading
protein. b Graph of the
densitometric values of ApoeR2
and VLDLR levels in the
experiment. Plots show
mean ± S.E.M. of five different
experiments. c Dab1
phosphorylation in the presence
of PrP(106–126) in reeler-derived
neurons. The quantification of
experiments is shown in d. Plots
show mean ± S.E.M. of two
different experiments. *P < 0.05,
ANOVABonferroni post hoc test.
e Graph of the percentage of the
PI fluorescence measures of
PrP(106–126) treated cultures.
Plots show mean ± S.E.M. of
three different experiments. f
Western blot determination of
reelin protein levels in primary
neuronal cultures after PrP(106–
126) treatment. Cultures were
treated with 80 μM PrP(106–126)
peptide for one in absence or
presence of NAC and DPI (see
the BMaterial and Methods^
section for details). Tubulin was
used as control loading protein
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Results indicated no statistically significant differences in
Reelin content between genotypes although Prnpo/o showed
a ∼ 6 % increase compared to wild type ((1.204 ± 0.19
(Prnpo/o) vs 1.128 ± 0.055 (Prnp+/+) vs 1.065 ± 0.215
(Tga20); mean ± S.E.M.) (Fig. 1b). Next, we aimed to corrob-
orate these results by analyzing RelnmRNA expression in the
neocortex of Prnp0/0 and Prnp+/+ with in situ hybridization
(Fig. 1c–e). Qualitative (Fig. 1c, d) and quantitative (Fig. 1e)
data corroborated that there were no relevant differences in the
Reln mRNA expression between the two genotypes.
Increased Reelin Expression in PrP(106–126)-Treated
Primary Cortical Neurons Does Not Correlate
with Activation of the Reelin Pathway
Peptides mimicking prion sequences (e.g., human or mouse)
have been used as models of prion-mediated cytotoxicity for
many years [62–65]. Thus, we aimed to check the effects of
PrP(106–126) in modifying Reelin protein levels in primary cor-
tical neurons (Figs. 2 and 3). First, to avoid the effects asso-
ciated with low endogenous expression of PrPC levels, these
were determined in primary cortical cultures at several days
in vitro (DIV) in order to establish the appropriate time win-
dow for treatments (Supplementary Fig. 1). Reasonable levels
of PrPC in cultures were detected after 12–15 days in vitro
(Supplementary Fig. 1). In a second set of experiments, corti-
cal neurons were maintained in vitro for 15 DIVand incubated
with 80 μM aggregated PrP(106–126) [66] for 30 min, 1 day,
and 4 days, and Reelin expression levels were analyzed
(Figs. 2a and 3). Parallel cultures were incubated with scram-
bled peptide, 0.1 M PBS, untreated as internal controls
(Fig. 2a). In addition, levels of Dab1 phosphorylation were
also checked after PrP(106–126) treatment (Fig. 3). Results in-
dicate that in the treated cultures, the upper band of 420 kD
and the lower band of 180 kD of cellular Reelin could be
easily distinguished in protein extracts (Fig. 2a and 3). In
addition, they showed a 1.25-fold increase in total Reelin at
24 h after PrP(106–126) treatment (P < 0.05, t = 2.819, 95 %
confidence interval of diff. = −08.699 to 0.04990 (1 vs 1 day +
PrP(106–126) )); ANOVABonferroni post hoc test (Fig. 3). This
Reelin increase can be seen, albeit reduced, 4 days after treat-
ment (1.21-fold increase) (P < 0.05, t = 3249, 95% confidence
interval of diff. = −0.7222 to −0.009744 (4 vs 4 day + PrP(106–
126)) ANOVA Bonferroni post hoc test) (Fig. 3). Surprisingly,
this increase in Reelin is delayed with respect to the increase in
p-Dab1 and degradation (Fig. 3). Indeed, increased p-Dab1
was observed shortly after 30 min of incubation with
PrP(106–126) (Fig. 3). This happens prior to the Reelin increase
(24 h) suggesting that early Dab1 phosphorylation is not me-
diated by Reelin (Fig. 3). In addition, this data suggests that
these changes in Reelin do not correlate with increased
Reelin-mediated signaling. This was also corroborated by an-
alyzing ApoER2 levels [67]. Changes in ApoER2 levels are
modulated by Reelin signaling [67]. However, ApoeR2 and
VLDLR levels remained constant during these periods, except
after 4 days in vitro, they were slightly changed without
reaching statistical signification (Fig. 2b). Quantification of
ApoeR2/Actin ratio was 0.62 ± 0.02 (untreated) vs
0 .41 ± 0 .09 (P rP ( 1 0 6 – 1 2 6 ) ) 1 day o f t r e a tmen t
(mean ± S.E.M.) and 0.34 ± 0,03 (untreated) vs 0.59 ± 0.09
(PrP(106–126)) 4 days of treatment (mean ± S.E.M.).
Quantification of VLDLR/Actin ratio was 0.69 ± 0.06
(un t r ea t ed) vs 0 .49 ± 0 .09 1 day of t r ea tment
(mean ± S.E.M.) and 0.53 ± 0.06 (untreated) vs 0.70 ± 0,10;
4 days of treatment (mean ± S.E.M.). Changes after 4 days
might reflect changes in cell death due to the amyloid treat-
ment. In fact, a higher level of cell death was monitored by
using propidium iodide uptake in PrP(106–126)-treated cultures
Fig. 3 a Parallel determination of reelin, p-Dab1, and Dab1 levels in
primary neuronal cultures after PrP(106–126) treatment. Cultures were
treated with 80 μM PrP(106–126) peptide for the times indicated (30 min,
1 day, and 3 days). Reelin-probed membranes were immunoblotted using
antibodies against tubulin for standardization. The phosphorylated form
of Dab1 was analyzed by immunoprecipitation and western blotting.
Membranes were re-probed with an antibody against total Dab1. b
Graph of the densitometric values of reelin and p-Dab1 levels. Plots
show mean ± S.E.M. of three different experiments
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compared to controls (PI staining = 62.65 ± 5.16, PrP(106–126)
vs 43.77 ± 3.23, scrambled, at 96 h of treatment) (Fig. 2e).
Next, in order to determine whether the fast Dab1 phosphor-
ylation observed after peptide treatment is related with Reelin,
we processed primary neuronal cultures obtained from reeler
mice. Treatment of reeler-derived cortical neurons lacking
reelin with PrP(106–126) is also able to increase p-Dab1
(0.293 ± 0.0159 (scrambled) vs 0.498 ± 0.033 (PrP(106–126)),
mean ± S.E.M., P < 0.05, t = 3.381, 95 % confidence interval
of diff. = −0.398 to −0.010; ANOVABonferroni post hoc test)
(Fig. 2c, d), reinforcing the notion that the presence of reelin is
not mandatory in the increased p-Dab1 levels mediated by
PrP(106–126). Increased kinase activity and high levels of
ROS have been described after prion infection [33, 66,
68–70] and in sCJD patients [33]. Thus, we aimed to explore
whether ROS generation in treated cultures participates in the
observed changes in Reelin expression. Results showed that
the ROS scavenger NAC and the NADPH oxidase inhibitor
DPI are able to block Reelin increase mediated by PrP(106–126)
(Fig. 2f).
Decreased Reelin Protein Levels in Prion-Inoculated Mice
Prnp+/+ were inoculated with 22L or Mo-BSE prions, and
cortical levels of Reelin were determined in cortical extracts
of terminal mice (137–138 days (22L) and 201–202 days
(Mo-BSE)). Developed film demonstrated a decrease in
Reelin levels in 22L-inoculated mice (0.5360 ± 0.028 (non-
inoculated) vs 0.2990 ± 0.055 (22L inoculated),
mean ± S.E.M., P < 0.05, t = 4.943; 95 % confidence interval
of diff. = 0.1188 to 0.4091; ANOVA Bonferroni post hoc test)
(Fig. 4). Mo-BSE-inoculated mice also showed reduced
Reelin content compared to non-inoculated mice
(0.3510 ± 0.026 (Mo-BSE inoculated), mean ± S.E.M.,
P < 0.05, t = 3.602; 95 % confidence interval of diff. = 0.0525
to 0.3755 (Fig. 4). This decrease in Reelin could be due to a
decrease in Reelin-expressing cells in affected brains. Thus,
terminal prion-inoculated mice (Prnp+/+) and time-matched
Prnp0/0 inoculated mice were histologically processed to
Relnwith in situ hybridization (Fig. 5). Cell counts of revealed
sections demonstrated that neither the distribution nor the total
number of Reln-positive cells was significantly modified in
the neo cortex of the inoculated mice compared with the con-
trols (Fig. 5). As Reelin is expressed mainly by cortical inter-
neurons in adult cortex (mainly in calbindin, calretinin, NPY-,
and somatostatin- but rarely on parvalbumin-, cholecystoki-
nin-, or VIP-positive interneurons) [71], we also analyzed the
number of calbindin- and parvalbumin-positive interneurons
in the neocortex of inoculated and control mice. Results
showed similar numbers of calbindin-positive cells in inocu-
lated and non-inoculated mice (Fig. 5b–h). In contrast, the
number of parvalbumin-positive cells decreased slightly
(≈16.3 %) in layers IV–VI of Prnp+/+-inoculated mice
(Fig. 5c–i) corroborating previous results [72]. Taken together,
these results indicate that a direct effect of changes in Reelin
protein levels on non-pyramidal neuron populations in inocu-
lated mice is unlikely.
Changes in Reelin Expression in CJD Post-Mortem
Samples and CJD-Inoculated Mice
Total levels of Reelin and RelnmRNA changes were analyzed
in human post-mortem samples of frontal cortex of CJD pa-
tients (Tables 1 and 2; Fig. 6). Although the data did not reach
a P value <0.05 (Type II vs control; t = 0,6165; 95 % confi-
dence interval of diff. = −0.312 to 0.421; ANOVA Bonferroni
post hoc test), the results indicated a tendency of higher level
of Reelin in CJD patients, especially in type II (5.450 ± 0.490
(type II) vs 4.973 ± 0.490 (type I) vs 4.203 ± 0.4214 (control))
(Fig. 6b). This tendency in CJD patients was also corroborated
Fig. 4 Example of western blotting determination of Reelin in 22L (a) or
Mo-BSE (b)-inoculated mice. c Histograms showing the densitometric
study. Plots show mean ± S.E.M. of each different type of mouse. Each
dot corresponds to one mouse. Asterisks indicate statistical differences
between groups. *P < 0.05; ANOVA Bonferroni post hoc test
Mol Neurobiol
by RT-qPCR (1.693 ± 0.382 (type II) vs 1.703 ± 0.5125 (type
I) vs 1.090 ± 0.2050 (control)) (Fig. 6c). In parallel, we also
aimed to determine mRNA levels of Reln in the cerebral cor-
tices of Tg340 mice inoculated with human Met/Met PrP type
1 inoculum (Fig. 6d). Tg340 mice inoculated with sCJD
showed a faster evolution of the infective process (around
180 days post-inoculum (DPi)) than 22L in Mo-BSE infected
mice). In addition, they showed increased levels of Reln
mRNA at these days post - inocula t ion (Fig . 6d)
(0.1245 ± 0.013 (Con) vs 0.2210 ± 0.026 (CJD);
mean ± S.E.M., 1.71 ± 0.23-fold increase; P = 0.0141;
t = 3.248; 95 % confidence interval of diff. = − 0.79 to
0.244). In previous DPi, asymptomatic mice (120 DPi) or
those with few symptoms (160 DPi), levels of Reelin were
identical to control mice (Fig. 6d). Unfortunately, processing
of paraffin-embedded Tg340 mice or post-mortem (CJD) hu-
man samples with formic acid impairs the use of current anti-
bodies against Reelin or Reln mRNA detection to expand
these biochemical data histologically.
Discussion
The glycoprotein Reelin plays relevant roles during develop-
ment, maturation, and adult synapse maintenance of the ner-
vous system. In addition, it plays a neuroprotective role in
Alzheimer’s disease against β-amyloid-associated cytotoxici-
ty [12, 47]. Unfortunately, its presence in brain parenchyma
decreases during normal development, aging, and neurode-
generation [36, 41, 42]. In addition, in Alzheimer’s disease,
Fig. 5 a-f Low power
photomicrograph illustrating the
distribution of Reel- (a, d),
calbindin- (CALB) (b, e), and
parvalbumin (PARV) (c ,f) -
positive neurons in the neocortex
of inoculated Prnp+/+ and Prnp0/0
mice. g–i Radial distribution of
Reln- (g), calbindin- (S.E.M.),
and parvalbumin (i)-positive
neurons in Prnp0/0 and Prnp+/+
adult inoculated mice. Calbindin-
positive cells were ascertained as
interneurons for quantification.
Cortical layers are indicated in the
S.E.M. axis. Layer VIa + VIb
were grouped. Bars represent the
mean ± S.E.M. of the total
number of cells counted in eight
consecutive sections of two
(Prnp+/+) and seven (Prnp0/0)
mice. No statistical differences in
the numbers of positive cells were
seen between genotypes, except
for parvalbumin-positive cells
located in layers IV–VI)
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Reelin seems not to be functional when generated in the pres-
ence ofβ-amyloid [46, 73]. Thus, Reelin-dependent induction
of Dab1 phosphorylation appeared reduced in the presence of
β-amyloid being unable to modulate the cleavage of ApoER2
[46].These functional changes in Reelin are likely associated
to changes in Reelin glycosylation [37]. These changes com-
promise its capacity to bind to ApoER2, impeding the ability
to decrease tau phosphorylation [46, 73]. A reduced Reelin
expression is associated with impaired signaling, resulting in
cognitive decline [24, 74]. Blockage of reelin signaling is
sufficient to impair memory [75]. Thus, impaired Reelin sig-
naling could contribute to the clinical symptoms and patho-
logical progression in neurodegeneration.
Although Reelin expression levels have been characterized
in some neural diseases (see the BIntroduction^ section for
references), no data have been published on natural TSEs or
on models of prion infection. Bearing this in mind, we sought
to determine whether Reelin levels changed in TSEs and to
check their putative changes as a putative diagnostic biomark-
er of prion diseases. First, we determined that levels of Reelin
were not modified with different doses of Prnp. This contrasts
with a decrease in Reelin in brain extracts of Prnp0/0 mice
reported by Devanathan and co-workers [76]. This difference
could be associated with the use of Zürich I Prnp0/0 mice [76]
in contrast to C57Bl6/J backcrossed B6.129 mice with lower
129Sv loci (our study; see also [77, 78] for details). In fact, we
determined that adult Reln mRNA levels were not modified
betweenPrnp0/0, Prnp+/+, and Tga20mice in a previous study
[77] as also observed by [79].
Table 2 Main clinical characteristics of sCJD and control cases in the
qRT-PCR study
Case number Gender Age Codon 129 PrP type
CJD1 F 72 MM 1
CJD2 M 46 MM 1
CJD3 M 64 MM 1
CJD4 M 66 MM 1
CJD5 M 70 MM 1
CJD6 M 66 VV 2
CJD7 F 76 VV 2
CJD8 M 65 VV 2
CJD9 F 47 VV 2
CJD10 M 54 VV 2
Control1 M 85
Control2 M 62
Control3 M 59
Control4 M 39
Control5 M 78
F female,Mmale,MMmethionine, V:valine, PrPsc type 1 lower band of
glycosylated PrPsc of 21 kD, type 2 lower band of glycosylated PrPsc of
10 kD
Fig. 6 Examples of western blotting determination of Reelin (a, b) and
Reln mRNA quantification by RT-qPCR (c) in sCJD cases compared to
controls. However, no statistically significant increased levels of Reelin
orRelnmRNA can be seen in the sCJD group (types I and II) compared to
controls. d Histograms showing results of Reln mRNA levels
(mean ± S.E.M.) in the cortex of Tg340 mice at 120, 160, and 180 DPI.
Each dot corresponds to one mouse. Asterisks indicate statistical differ-
ences between groups and controls. *P < 0.05; ANOVA Bonferroni post
hoc test
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Our results indicate that Reelin increased in primary cultures
when treated with 80 μM aggregated peptides mimicking hu-
man PrPC, in post-mortem cortical samples of CJD patients and
in the neocortex of infected mice with sCJD type I inoculum. In
contrast, mice inoculated with 22L andMo-BSE prions showed
decreased Reelin levels. In this respect, although a clear expla-
nation is not yet available, differences between mouse prion
diseases (22L and Mo-BSE) and sCJD in both human and
Tg340 mice could be related to prion strain properties. In fact,
similar differences between mice and human TSEs have also
recently been reported for Tau content and its phosphorylated
form [80]. On the other hand, a recent study reported that Tau,
and more specifically p-Tau levels, decreased in brain paren-
chyma of CJD patients [60]. Reelin acting through Dab1 phos-
phorylation increases Akt-Pi3K activation, decreasing GSK3β
activity and levels of p-Tau [18, 19]. Thus, it is reasonable to
consider that increased levels of Reelin (if functional) in CJD
patients (type I and II of PrP) may contribute to maintaining or
decreasing levels of p-Tau.
With respect to the in vitro data, we were surprised by the
increase in Reelin after peptide treatment, and so we checked
previous reported data using similar cultures. It is well known
that primary cultures treated with 80 μM PrP(106–126) show acti-
vatedAkt [66]. However, Simon et al. reported decreased activity
of PI3K and Akt in the cerebellum of inoculated mice and neu-
ronal cultures after PrP(106–126) (40 μM) incubation [81, 82], as
we foundwith lower doses of PrP(106–126) [66]. In our experience,
these differences are likely to be associated with the handling,
preparation, and concentration of the PrP(106–126) used for the
experiments. High concentrations of PrP(106–126) increase ROS
production in treated cells (Fig. 2) (see also [66, 69, 83]). In this
study, we showed that the increase in Reelin after PrP(106–126)
incubation could be linked to a burst of ROS production induced
by the peptide. ROS increase runs in parallel to the relevant
kinase activation reported after the inoculation of (263 K) [33]
or RML [48, 66] prions as well as human prion peptides [66, 68].
In addition, our results also point the need of different approaches
(in vivo and in vitro) to analyze prion-derived effects. For exam-
ple, human-derived peptides are able to induce Dab1 phosphor-
ylation in Reln-derived neurons. Further studies are needed to
ascertain the molecular actor/s involved and other kinases are
able to increase Dab1 phosphorylation in the absence of reelin
as described during development [84].
Due to that mRNA and protein levels in CJD and sCJD-
infected mice only occur at the final stages of the disease, we
believe that the increased Reelin changes are likely associated
with the profound metabolic changes (e.g., cellular stress, in-
flammation, etc.) strongly present in the last stages of the
infective process. In addition, this invites the question of
whether the increased Reelin levels observed in CJD and
Tg340 mice also correspond to a Bnon-functional^ protein
has indicated in AD. In fact, low Dab1 phosphorylation is
observed in sCJD PrP type II in the presence of the highest
levels of Reelin observed in the study (see [50] for descrip-
tion) and levels of p-Tau (normally decreased by functional
Reelin) were higher in similar sCJD samples [60, 85].
Levels of p-Tau and Tau have been suggested as a potential
biomarker in prionopathies such as the 14-3-3 protein [60, 85,
86]. Reln was associated as a susceptible gene in Alzheimer’s
disease but not in Parkinson’s disease [87]. However, increased
levels of a Reelin band of 180 kD have been determined in CSF
of AD, Parkinson’s disease [37], and frontotemporal dementia
[38]. In these neurodegenerative diseases, whether it is the case
that Reelin participates in the onset of the disease or its alteration
is a secondary effect of the neurodegeneration still remains elu-
sive. Thus, with the present results, it is reasonable to consider
that observed changes in Reelin at advanced stages of the
prionopathies are secondary to the degenerative process and
are probably associated with the physiological changes observed
in the disease [88, 89]. In conclusion, Reelin increase is not
associated with the processes linked to early onset of disease
and is therefore not a potential biomarker for prionopathies.
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